ROYAL BANK OF CANADA - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 66 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$134,000
+15.5%
8,059
+91.1%
0.00%
Q2 2023$116,000
+90.2%
4,217
+60.1%
0.00%
Q1 2023$61,000
+1.7%
2,634
-52.5%
0.00%
Q4 2022$60,000
+757.1%
5,543
+583.5%
0.00%
Q3 2022$7,000
+75.0%
811
+59.0%
0.00%
Q2 2022$4,000
-94.4%
510
-83.0%
0.00%
Q1 2022$71,000
-79.4%
3,000
-70.2%
0.00%
Q4 2021$345,000
+305.9%
10,067
+110.4%
0.00%
Q3 2021$85,000
-43.0%
4,785
+43.7%
0.00%
Q2 2021$149,000
+73.3%
3,330
+0.2%
0.00%
Q1 2021$86,000
+258.3%
3,324
+179.3%
0.00%
Q4 2020$24,000
+140.0%
1,190
+138.0%
0.00%
Q3 2020$10,000
+11.1%
5000.0%0.00%
Q2 2020$9,000500
+861.5%
0.00%
Q1 2020$0
-100.0%
52
-95.3%
0.00%
Q4 2019$8,000
+166.7%
1,102
+120.4%
0.00%
Q4 2018$3,000
-40.0%
500
-1.4%
0.00%
Q3 2018$5,000
+66.7%
507
+26.8%
0.00%
Q2 2018$3,000
+50.0%
400
+122.2%
0.00%
Q1 2018$2,000
+100.0%
180
+153.5%
0.00%
Q4 2017$1,000
-92.3%
71
-90.6%
0.00%
Q3 2017$13,000
+1200.0%
758
+1357.7%
0.00%
Q2 2017$1,000
-66.7%
52
-78.6%
0.00%
Q1 2017$3,000
-62.5%
243
-31.9%
0.00%
Q4 2016$8,000
+100.0%
357
+78.5%
0.00%
Q3 2016$4,0002000.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Pharmstandard International S.A. 750,632$7,724,00026.59%
BVF INC/IL 2,617,967$26,939,0002.37%
GREAT POINT PARTNERS LLC 982,449$10,109,0001.58%
Alambic Investment Management, L.P. 65,128$670,0000.53%
FARALLON CAPITAL MANAGEMENT LLC 2,243,202$23,083,0000.14%
ALGERT GLOBAL LLC 44,477$458,0000.10%
Monashee Investment Management LLC 42,945$442,0000.09%
Tekla Capital Management LLC 219,042$2,254,0000.08%
Spark Investment Management LLC 138,800$1,428,0000.08%
OXFORD ASSET MANAGEMENT LLP 187,653$1,904,0000.04%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders